Nanoparticle Uptake Pathways in Human Corneal Epithelial Cells: Insights from PLGA Systems

Study Background and Research Question

Ocular drug delivery remains a formidable challenge in pharmaceutical sciences. Topically administered ophthalmic drugs are preferred for patient compliance and are the dominant marketed products, yet they often suffer from low bioavailability due to rapid clearance from the eye surface and poor tissue penetration. The primary barriers include the complex tear film and the multi-layered cornea, whose superficial epithelium accounts for most of the corneal barrier function. While numerous strategies—such as viscosity enhancers, penetration enhancers, and in situ gels—have been tried to overcome these obstacles, side effects like irritation and blurred vision limit their use. As a result, nanoparticle-based delivery systems, especially those employing polymeric carriers like PLGA (poly(lactic-co-glycolic) acid), have become a focus of research due to their customizability and potential for sustained release. However, there remains a knowledge gap regarding how the physicochemical properties of nanoparticles—particularly size and surface chemistry—govern their cellular uptake by human corneal epithelial cells (HCECs). The central question addressed by the reference study is: how do these properties modulate the mechanisms and efficiency of nanoparticle internalization in HCECs?

Key Innovation from the Reference Study

The primary innovation of the study lies in the systematic dissection of nanoparticle uptake pathways as a function of both size and surface modification. By engineering monodisperse PLGA nanoparticles (100–250 nm) with distinct surface chemistries—mucoadhesive (alginate, chitosan) and mucopenetrative (PEG)—the researchers could parse out the contributions of different endocytotic mechanisms in HCECs. This approach moves beyond previous work by not only characterizing uptake efficiency but also pinpointing the predominant entry routes, thus offering granular design rules for next-generation ocular nanocarriers.

Methods and Experimental Design Insights

The research team synthesized PLGA nanoparticles using the emulsion-solvent evaporation technique, ensuring monodispersity (PDI < 0.2) and spherical morphology. Surface modifications were carried out with polymers imparting either mucoadhesive (alginate [ALG], chitosan [CHS]) or mucopenetrative (polyethylene glycol [PEG]) properties. The resulting nanoparticles had controlled size (100–250 nm) and zeta potentials ranging from −25 to +15 mV.

For biological evaluation, the study employed an in vitro HCEC monolayer integrated with a simulated mucosal solution to mimic the ocular surface. Cytotoxicity was assessed via MTT assay after 24-hour nanoparticle exposure at concentrations up to 100 μg/mL, revealing only mild toxicity (70–100% cell viability). Cellular uptake was quantified, and mechanistic studies utilized pharmacological inhibitors to delineate specific endocytic pathways.

Protocol Parameters

• Nanoparticle preparation: Emulsion-solvent evaporation to achieve 100–250 nm size range with PDI < 0.2.
• Surface modification: Post-synthesis coating with alginate, chitosan, or PEG to impart mucoadhesive or mucopenetrative properties.
• Cytotoxicity testing: Incubation with HCECs at 1–100 μg/mL for 24 h; MTT assay for viability.
• Cellular uptake assay: In vitro HCEC monolayer under simulated mucosal conditions; quantification by fluorescence or confocal microscopy.
• Pathway inhibition: Use of specific inhibitors to block clathrin-mediated, caveolae-mediated, and macropinocytosis pathways.

Core Findings and Why They Matter

Energy-dependent endocytosis was identified as the principal mechanism for nanoparticle uptake by HCECs. Among the PLGA nanoparticles studied, those with a 100 nm diameter and PEG surface modification (PEG-PLGA-150 NPs) exhibited the highest uptake efficiency. Mechanistically, macropinocytosis and caveolae-mediated endocytosis were the dominant internalization pathways, while clathrin-mediated endocytosis contributed to a lesser extent. Phagocytosis did not play a significant role for the tested size and surface chemistries.

These findings have immediate implications for ocular drug delivery design:

• Optimizing nanoparticle size to around 100–150 nm maximizes cellular internalization by HCECs.
• Surface PEGylation enhances both mucopenetration and uptake, likely due to reduced nonspecific interactions with the mucin layer.
• Understanding dominant uptake mechanisms allows for rational selection of surface ligands or drug conjugates that exploit macropinocytosis or caveolae-mediated pathways.

Importantly, the mild cytotoxicity profile supports the feasibility of using such nanoparticles for repeated topical administration in ocular therapies, addressing a key safety concern.

Comparison with Existing Internal Articles

The present study builds upon and extends the mechanistic insights reported in internal resources such as "Nanoparticle Uptake in Corneal Cells: Role of Physicochemical Properties" and "Nanoparticle Uptake in Corneal Cells: Role of Size and Surface Chemistry". Both of these articles highlight the influence of nanoparticle size and surface characteristics on internalization mechanisms, corroborating that energy-dependent endocytosis—particularly macropinocytosis and caveolae-mediated entry—predominates in HCECs. The reference study advances these concepts by providing a direct, side-by-side comparison of multiple nanoparticle formulations under standardized conditions and by employing a robust inhibitor profiling approach to deconvolute uptake pathways.

Additionally, the intersection with actin polymerization research is noteworthy. Studies like "Cytochalasin D: Advanced Insights into Actin Polymerization Inhibition" and "Cytochalasin D: Mechanistic Insights and Translational Potential" discuss how actin dynamics regulate endocytosis and cellular barrier properties. The application of actin polymerization inhibitors such as Cytochalasin D in uptake studies provides a powerful tool to dissect these mechanisms, further supporting the relevance of actin-targeted reagents in nanoparticle delivery research.

Limitations and Transferability

Despite its systematic approach, the study is limited by its in vitro model, which, although incorporating a simulated mucosal solution, cannot fully recapitulate the dynamic tear film and blinking action present in vivo. The nanoparticle formulations were restricted to PLGA-based systems and selected surface modifications, so the findings may not be directly extensible to other polymer types or to particles with more complex surface architectures. Additionally, the lack of in vivo pharmacokinetic or efficacy data means that barriers such as conjunctival clearance, immune surveillance, and systemic absorption remain to be addressed.

The results are most directly transferable to preclinical screening of ocular nanocarriers and to the rational selection of nanoparticle parameters for further translational development. Researchers should be cautious when extrapolating these findings to non-ocular tissues or to disease states with altered corneal or mucosal properties.

Why this cross-domain matters, maturity, and limitations

The mechanistic understanding of cellular uptake pathways is broadly relevant for any context where nanoparticle penetration of epithelial barriers is desired. However, the study’s focus is specifically on ocular epithelial cells, and while core principles of endocytosis may generalize, tissue-specific differences in mucosal structure, receptor expression, and local immune environment can significantly alter uptake dynamics. Further research is needed to validate these mechanisms in vivo and across different epithelial models.

Research Support Resources

Researchers aiming to replicate or extend these uptake studies may require precise modulation of cytoskeletal dynamics to parse endocytic routes. Cytochalasin D (SKU B6645) from APExBIO is a well-characterized actin polymerization inhibitor with nanomolar potency, frequently used to disrupt actin-dependent endocytosis or to induce cell cycle arrest at the G1-S transition. For optimal results in cell culture assays, concentrations in the range of 0.2–0.5 μg/mL are commonly employed, as indicated in the product information. This reagent can support mechanistic studies of nanoparticle internalization or serve as a control in cellular trafficking experiments. Solutions should be prepared fresh and used promptly to maintain activity.